Stock Evaluator: Odyssey Therapeutics, Inc. (ODTX)

Odyssey Therapeutics, Inc. ODTX

$16.96 -1.38 -7.52%
November 20, 2026 3:59:59 PM EST November 10, 2021 Volume: 677,842
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics ODTX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $808.8 $203.5 44%
Shares Out (Mil) 48.0 55.2 46%
Institutional Ownership 95.0% 93.3% 66%
Float (Mil) 23.7 40.4 31%
Beta na 1.05 na
Avg Daily Volume (000s) 401 569 54%
Price Change
(52-week)
na 38.8% na
Growth ODTX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) na (10.7%) na
EPS (5yr) na 15.4% na
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) na (15.7%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 2 3
Current EPS ($1.030) ($5.600) ($4.436)
Month Ago EPS ($1.006) ($4.110) ($4.360)
# Rev Up 0 0 0
# Rev Down 1 0 1
Three Months Ago EPS ($1.006) ($4.255) ($4.360)
Year/Year Chg (6.8%) (88.8%) (90.6%)
Financials ODTX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $40 na
Net Income (TTM) (Mil) ($178) ($44) 7%
EPS (TTM) ($7.956) ($1.400) 5%
Operating Cash Flow (TTM) (Mil) ($142) ($35) 5%
Net Cash Flow (TTM) (Mil) ($74) $-0 18%
Long-Term Debt (Q1) (Mil) $18 $4 32%
Enterprise Value (Q1) (Mil) $542 $142 36%
Valuation ODTX Industry
Median
Percentile
(All Stocks)
P/B 2.15 1.96 61%
P/E na 16.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios ODTX Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (81.1%) (47.0%) 7%
ROE (94.5%) (51.8%) 9%
Liabilities to Assets 14.2% 29.6% 9%
F-Score 1 3 na

Odyssey Therapeutics, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors